

**UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ALABAMA
SOUTHERN DIVISION**

JULIET OWENS, }
Plaintiff, }
v. } **Case No.: 2:15-CV-00815-MHH**
CAROLYN W. COLVIN, }
Commissioner of the }
Social Security Administration, }
Defendant. }

MEMORANDUM OPINION

Pursuant to 42 U.S.C. §§405(g) and 1383(c), plaintiff Juliet Owens seeks judicial review of a final adverse decision of the Commissioner of Social Security. The Commissioner denied her claims for a period of disability and disability insurance benefits and supplemental security income. After careful review, the Court reverses the Commissioner's decision.

I. PROCEDURAL HISTORY

Ms. Owens applied for a period of disability and disability insurance benefits and supplemental security income on August 14, 2012. (Doc. 7-6, pp. 2, 9). Ms. Owens alleges that her disability began on July 10, 2012. (Doc. 7-6, pp. 2, 9). The Commissioner initially denied Ms. Owens claims on November 28,

2012. (Doc. 7-5, p. 2). Ms. Owens requested a hearing before an Administrative Law Judge (ALJ). (*Id.* at 16-17). The ALJ issued an unfavorable decision on February 4, 2014. (Doc. 7-3, pp. 11-19). On March 17, 2015, the Appeals Council declined Ms. Owens's request for review (*Id.* at 1), making the Commissioner's decision final and a proper candidate for this Court's judicial review. *See* 42 U.S.C. §§405(g) and 1383(c).

II. STANDARD OF REVIEW

The scope of review in this matter is limited. "When, as in this case, the ALJ denies benefits and the Appeals Council denies review," the Court "review[s] the ALJ's 'factual findings with deference' and [his] 'legal conclusions with close scrutiny.'" *Riggs v. Comm'r of Soc. Sec.*, 522 Fed. Appx. 509, 510-11 (11th Cir. 2013) (quoting *Doughty v. Apfel*, 245 F.3d 1274, 1278 (11th Cir. 2001)).

The Court must determine whether there is substantial evidence in the record to support the ALJ's findings. "Substantial evidence is more than a scintilla and is such relevant evidence as a reasonable person would accept as adequate to support a conclusion." *Crawford v. Comm'r of Soc. Sec.*, 363 F.3d 1155, 1158 (11th Cir. 2004). In making this evaluation, the Court may not "decide the facts anew, reweigh the evidence" or substitute its judgment for that of the ALJ. *Winschel v. Comm'r of Soc. Sec. Admin.*, 631 F.3d 1176, 1178 (11th Cir. 2011) (internal quotations and citation omitted). If the ALJ's decision is supported by substantial

evidence, the Court “must affirm even if the evidence preponderates against the Commissioner’s findings.” *Costigan v. Comm’r, Soc. Sec. Admin.*, 603 Fed. Appx. 783, 786 (11th Cir. 2015) (citing *Crawford*, 363 F.3d at 1158).

With respect to the ALJ’s legal conclusions, the Court must determine whether the ALJ applied the correct legal standards. If the Court finds an error in the ALJ’s application of the law, or if the Court finds that the ALJ failed to provide sufficient reasoning to demonstrate that the ALJ conducted a proper legal analysis, then the Court must reverse the ALJ’s decision. *Cornelius v. Sullivan*, 936 F.2d 1143, 1145-46 (11th Cir. 1991).

III. SUMMARY OF THE ALJ’S DECISION

To determine whether a claimant has proven that she is disabled, an ALJ follows a five-step sequential evaluation process. The ALJ considers:

- (1) whether the claimant is currently engaged in substantial gainful activity; (2) whether the claimant has a severe impairment or combination of impairments; (3) whether the impairment meets or equals the severity of the specified impairments in the Listing of Impairments; (4) based on a residual functional capacity (“RFC”) assessment, whether the claimant can perform any of his or her past relevant work despite the impairment; and (5) whether there are significant numbers of jobs in the national economy that the claimant can perform given the claimant’s RFC, age, education, and work experience.

Winschel, 631 F.3d at 1178.

In this case, the ALJ found that Ms. Owens has not engaged in substantial gainful activity since July 10, 2012, the alleged onset date. (Doc. 7-3, p. 12). The

ALJ determined that Mr. Plaintiff suffers from “the following severe impairments: cervical radiculopathy with bilateral upper extremity involvement.” (*Id.*). The ALJ also determined that Ms. Owens has type II diabetes and mild atrophy associated with a stroke, but neither is a severe impairment. (*Id.* at 13). Based on a review of the medical evidence, the ALJ concluded that Ms. Owens “does not have an impairment or combination of impairments that meets or medically equals the severity of any of the listed impairments in 20 C.F.R. Part 404, Subpart P, Appendix 1.” (*Id.*).

Next, the ALJ determined that Ms. Owens has the residual functional capacity (“RFC”) to perform sedentary work except:

the claimant is able to occasionally balance, stoop, kneel, crouch, crawl and climb ramps and stairs but never ladders, ropes or scaffolds; must avoid vibration, unprotected heights and hazardous machinery; is able to occasionally reach overhead with right dominant extremity; may perform no overhead work with the left upper extremity; will be off task 10% of the day.

(*Id.*). Based on this RFC, the ALJ concluded that Ms. Owens is not able to perform her past relevant work as a kriller or as a CNA. (*Id.* at 17). Relying on testimony from a vocational expert concerning hypotheticals that the ALJ posed, the ALJ found that jobs exist in the national economy that Ms. Owens can perform, including document preparer, telephone information clerk, and product assembler. (*Id.* at 18). Accordingly, the ALJ determined that Ms. Owens has not been under a disability within the meaning of the Social Security Act. (*Id.* at 19).

IV. ANALYSIS

Ms. Owens argues that she is entitled to relief from the ALJ's decision because the ALJ failed to properly evaluate her testimony of disabling symptoms consistent with the Eleventh Circuit's three part pain standard. The Court agrees.¹

“To establish a disability based on testimony of pain and other symptoms, the claimant must satisfy two parts of a three-part test by showing ‘(1) evidence of an underlying medical condition; and (2) either (a) objective medical evidence confirming the severity of the alleged pain; or (b) that the objectively determined medical condition can reasonably be expected to give rise to the claimed pain.’”

Zuba-Ingram v. Commissioner of Social Sec., 600 Fed. Appx. 650, 656 (11th Cir. (2015) (quoting *Wilson v. Barnhart*, 284 F.3d 1219, 1225 (11th Cir. 2002) (per curiam)). A claimant's testimony coupled with evidence that meets this standard “is itself sufficient to support a finding of disability.” *Holt v. Sullivan*, 921 F.2d 1221, 1223 (11th Cir. 1991) (citation omitted). If the ALJ discredits a claimant's subjective testimony, the ALJ “must articulate explicit and adequate reasons for doing so.” *Wilson*, 284 F.3d at 1225. “While an adequate credibility finding need not cite particular phrases or formulations[,] broad findings that a claimant lacked credibility . . . are not enough. . . .” *Foote v. Chater*, 67 F.3d 1553, 1562 (11th Cir.

¹ Ms. Owens also alleges that the ALJ did not properly evaluate the opinion of Dr. Englert. (Doc. 9, p. 8). Because the Court finds the first issue meritorious, the Court will not address this additional issue.

1995) (per curiam); *see* SSR 96-7P, 1996 WL 374186 at *2 (“The determination or decision must contain specific reasons for the finding on credibility, supported by the evidence in the case record, and must be sufficiently specific to make clear to the individual and to any subsequent reviewers the weight the adjudicator gave to the individual’s statements and the reasons for that weight”).

Ms. Owens testified at her hearing “I can’t do the stuff that I used to do... it’s hard, you know, lifting stuff. And with my neck, it’s hard for me to turn my neck certain ways. And the pain goes through my neck and down my shoulder.” (Doc. 7-3, pp. 30, 32). Ms. Owens testified that she could not cook, clean, do laundry, participate in her stepson’s extracurricular activities, or drive due to the pain in her neck. (*Id.* at 30-31). Ms. Owens stated that she “can’t lift” up her left arm without losing “strength in [her] hand and [her] arm.” (*Id.* at 33). Ms. Owens reported that she could “lift things over [her] head” with her right arm, but not her left arm. (*Id.*). She estimated she could lift “not over five pounds” before losing her grip strength. (*Id.* at 34). Ms. Owens testified that her anti-inflammatory medication would occasionally control her pain, but it made her sleepy and made focusing difficult. (*Id.* at 36). Even on her medication though, her pain would be debilitating because she is “sitting up all day, and all night.” (*Id.*). She testified that she spent “at least four or five” hours during normal work hours in bed to

control her pain. (*Id.* at 47). Ms. Owens testified the severity and intensity of her pain was, on average, a nine out of ten. (*Id.* at 46).

Taken as a whole, Ms. Owens's subjective pain testimony concerns her neck and her left arm. Because of the pain in these locations, she alleges that she cannot perform basic domestic tasks, cannot functionally lift with her left arm, and is bedridden at least half of a normal workday.

The ALJ summarized Ms. Owens's testimony. (*Id.* at 14). The ALJ properly recited the pain standard by finding that Ms. Owens's "medically determinable impairments could reasonably be expected to cause the alleged symptoms." (*Id.*). The ALJ then found that Ms. Owens's testimony concerning the "intensity, persistence and limiting effects" of her symptoms was not credible. (*Id.* at 15).

The ALJ stated that "objective medical evidence" and "treatment notes" undermine Ms. Owens's subjective testimony on her "alleged cervical impairments." (*Id.*). Substantial evidence does not support the ALJ's interpretation of Ms. Owens's medical records. Ms. Owens's treatment notes are consistent with her subjective pain testimony.

On July 16, 2012, Ms. Owens visited Dr. Robert Agee at Lemak Sports Medicine. (Doc. 7-8, p. 119). Ms. Owens had "pain on palpation of her neck at C5-C6, which is going to the left side. Which showed decreased sensation on the

left and decreased strength on the other side.” (*Id.*). X-Ray results showed “degenerative disk disease with multiple two level C4-C5, C5-C6 with some neural foraminal narrowing.” (*Id.*). Dr. Agee noted Ms. Owens’s chief complaint was “neck pain” and continuing “pain that is going down her left arm.” (*Id.* at 118). Dr. Agee did not believe the patient was incredible.

During an August 6, 2012 recheck, Dr. Agee found Ms. Owens had “decreased pain, but still a fair amount of pain.” (*Id.* at 117). Dr. Agee opted to try an epidural treatment and therapy to combat her pain and lack of flexibility. (*Id.*).

On August 27, 2012, Dr. Agee noted that Ms. Owens continued “to have pain in her cervical spine... with radiating [pain] down her left arm. She continues to hurt on the left side and thinks she has spasm.” (*Id.* at 116). Dr. Agee opined “she still has decreased range of motion. Still positive Spurling [test]. Pain radiating down her left side.” (*Id.*). Dr. Agee refilled her “medications of Flexeril, Naprosyn, and Lortab.” (*Id.*). He decided to keep her out of work until she could see a specialist, Dr. J. Stanford Faulkner. (*Id.*). Dr. Agee noted that Ms. Owens “has had no improvement with the conservative treatment of two epidural therapies, Medrol Dosepak, and pain medication hasn’t given her any relief.” (*Id.*).

Dr. J. Stanford Faulkner examined Ms. Owens one month later. Harry Wheelock, PA, wrote the report. (*Id.* at 115). Mr. Wheelock noted Ms. Owens’s

consistent pain complaints. (*Id.*). An examination found “exquisite tenderness to the cervical spine with severe pain on motion and limitation of motion. Positive Spurling’s [test] on the left. She has got some swelling in her... left shoulder.... She has some weakness in her deltoids especially on the left.” (*Id.* at 114). An X-Ray and MRI performed on Ms. Owens supported her complaints. (*Id.*).

Dr. Faulkner examined Ms. Owens on October 3, 2012 to determine if she had a mass in her shoulder. She did not. (*Id.* at 110). The negative test enabled Dr. Faulkner to begin Ms. Owens on a nerve root block to reduce her pain. (*Id.*). Dr. Faulkner examined Ms. Owens’s motion range during this visit. He found that her spine movement was reduced by roughly half of the normal range. (*Id.* at 86). Ms. Owens’s right arms suffered no real limitations, while her left arm movement was reduced to half of the normal motion range, not counting her near-normal external rotation. (*Id.*).

On October 29, 2012, Dr. Abiodun Badewa examined Ms. Owens at the request of the State agency. (Docs. 7-3, p. 16; 7-8, p. 121). Dr. Badewa noted Ms. Owens “is presented with neck pain.... It is described as aching and chronic.... The frequency of episodes is daily.... It is radiating down the left arm. The complaint is severe 8/10.” (Doc. 7-8, p. 121). During the consultative examination, Dr. Badewa tested Ms. Owens’s flexibility and confirmed Dr.

Faulkner's results from earlier in the month. (*Id.* at 125). Dr. Badewa did not note a specific cause of the pain during the examination.

In 2013, Ms. Owens started receiving treatment at Cooper Green after losing her insurance. (Doc. 7-3, pp. 44-45). During a March 14, 2013 visit, Dr. Nassif Cannon noted that Ms. Owens had several blocks but continued to experience pain "to her left arm and back from neck." (Doc. 7-8, p. 139). Ms. Owens's vertebral bodies were tender, her left arm strength was "3/5," and when she elevated her left arm, she experienced a "tremor" with "decreased sensations." (*Id.* at 140). Like the physicians before him, Dr. Cannon did not find Ms. Owens's account of her pain to be incredible.

On May 17, 2013, Ms. Owens saw a Cooper Green neurologist for "[n]eck and shoulder pain." (*Id.* at 137). Ms. Owens complained "of worsening pain, which rates a 7-9 of 10 and varies throughout the day, but is present every day. She also complains of left hand and arm 'tingling' and pain progressing from her neck to her right shoulder." (*Id.*). The examining physician ordered an MRI of Ms. Owens's cervical spine to compare her current results to those from an MRI in July 2012. Treatment records from this visit indicate that "conservative medical management" had failed and that Ms. Owens "continues to have pain." (*Id.* at 138).

Medical records from June 12, 2013 present one exception to Ms. Owens's longitudinal treatment history: her left and right arms had a "full range of motion," though her cervical spine was still "limited." (*Id.* at 136). The limited movement was accompanied by "neck pain." (*Id.* at 135).

On August 2, 2013, Ms. Owens returned to Cooper Green's neurology clinic. (*Id.* at 132). Under general observations, the doctor wrote, "patient sitting on bed, apparently in pain." (Doc. 7-8, p. 133). Ms. Owens reported that since her visit in May, she believed her pain had "been stable and somedays a bit worse." (*Id.*). Ms. Owens complained that "she has knots of her [left] shoulder and her [right] thumb gets stuck." (*Id.*). She rated her pain as "7-9 of 10," varying throughout the day. (Doc. 7-8, p. 132). Treatment records revealed that Ms. Owens "has been relying heavily on her husband to help with chores around the house for the past year. Her husband thinks that things have been about the same over the past year." (*Id.*). The physician referred Ms. Owens to the pain clinic at UAB. (*Id.* at 133).

On December 6, 2013, Ms. Owens reported "having continued cervicalgia with pain radiating down her arm as well as paresthesias in her hand." (*Id.* at 128). A neurological exam found "pronounced weakness as follows: WE 3/5, WF 4/5, HI 4/5, APB 3/5, FE 3/5." (*Id.* at 129). All other neurological signs appeared normal with the exception of decreased senses in C6-7 on the right and median

optionally, through a linker (L) to the chelator portion of the compounds. The chelator portion comprises an α , β -diaminopropionic acid moiety linked to a cysteine group through a third amino acid residue. The chelator portion of the compound is adapted to bind a radionuclide cation (M) (where k = 1).

5 In accordance with the invention, the compounds with bound radionuclide are referred to as "vitamin-imaging agent conjugates."

The structure of the linker, if present, is not critical to the invention. Thus, for example, it can be any biocompatible divalent linker. Typically, the linker comprises about 1 to about 30 carbon atoms, more typically about 2 to about 20 carbon atoms. Lower molecular weight linkers (*i.e.*, those having an approximate molecular weight of about 30 to about 300) are typically employed. Furthermore, the vitamin moiety may be a vitamin, or a derivative or analog thereof. For example, folate contains one glutamic acid in the L configuration linked to pteroic acid. As shown in Fig. 1, EC20 comprises a folic acid analog linked to the chelator moiety because EC20 has the glutamic acid in the D configuration. EC11 and EC14 contain two glutamic acid residues and, thus, these compounds can also, for example, be considered derivatives of folic acid (Fig. 10).

Among vitamins believed to trigger receptor-mediated endocytosis and having application in accordance with the presently disclosed method are niacin, 20 pantothenic acid, folic acid, riboflavin, thiamine, biotin, vitamin B₁₂, and the lipid soluble vitamins A, D, E and K. These vitamins, and their analogs and derivatives, constitute vitamins that can be coupled with imaging agents to form the vitamin-chelator conjugates for use in accordance with the invention. Preferred vitamin moieties include folic acid, biotin, riboflavin, thiamine, vitamin B₁₂, and analogs and 25 derivatives of these vitamin molecules, and other related vitamin receptor-binding molecules.

Folic acid, folinic acid, pteroic acid, pteropolyglutamic acid, and folate receptor-binding pteridines such as tetrahydropterins, dihydrofolates, 30 tetrahydrofolates, and their deaza and dideaza analogs can be used in accordance with the invention. The terms "deaza" and "dideaza" analogs refers to the art-recognized folate analogs having a carbon atom substituted for one or two nitrogen atoms in the naturally occurring folic acid structure. For example, the deaza analogs include the 1-

-12-

deaza, 3-deaza, 5-deaza, 8-deaza, and 10-deaza analogs. The dideaza analogs include, for example, 1,5 dideaza, 5,10-dideaza, 8,10-dideaza, and 5,8-dideaza analogs. The foregoing are folate analogs or derivatives and can bind to folate receptors. Other folate analogs or derivatives useful in accordance with the invention are the folate receptor-binding analogs aminopterin, amethopterin (methotrexate), N¹⁰-methylfolate, 2-deamino-hydroxyfolate, deaza analogs such as 1-deazamethopterin or 3-deazamethopterin, and 3'5'-dichloro-4-amino-4-deoxy-N¹⁰-methylpteroylglutamic acid (dichloromethotrexate).

The vitamin, or derivative or analog thereof, can be capable of selectively binding to the population of cells to be visualized due to preferential expression on the targeted cells of a receptor for the vitamin, or derivative or analog, wherein the receptor is accessible for binding. The binding site for the vitamin can include receptors for any vitamin molecule capable of specifically binding to a receptor wherein the receptor or other protein is uniquely expressed, overexpressed, or preferentially expressed by the population of cells to be visualized. A surface-presented protein uniquely expressed, overexpressed, or preferentially expressed by the cells to be visualized is a receptor not present or present at lower amounts on other cells providing a means for selective, rapid, and sensitive visualization of the cells targeted for diagnostic imaging using the vitamin-imaging agent conjugates of the present invention.

In accordance with the invention the vitamin-imaging agent conjugates are capable of high affinity binding to receptors on cancer cells or other cells to be visualized. The high affinity binding can be inherent to the vitamin moiety or the binding affinity can be enhanced by the use of a chemically modified vitamin (*i.e.*, an analog or a derivative) or by the particular chemical linkage between the vitamin and the chelator moiety that is present in the conjugate.

In accordance with the invention, the chelator can be conjugated with multiple, different vitamins, or vitamin receptor binding derivatives or analogs, to enhance the opportunity for binding to the respective cell membrane receptors. Alternatively, independent portions of the dose of a vitamin-imaging agent conjugate can constitute different vitamin-imaging agent conjugates to enhance the opportunity for binding to the respective cell membrane receptors.

-13-

Generally, any manner of forming a complex between the chelator and the vitamin, or vitamin receptor binding derivative or analog, can be utilized in accordance with the present invention. The chelator can form a complex with the vitamin, or vitamin receptor binding derivative or analog, by direct conjugation of the chelator and the vitamin by using a divalent linker. Alternatively, the vitamin and the chelator may be conjugated without employing a linker. If a linker is used, the linker can directly conjugate the vitamin, or vitamin receptor binding derivative or analog, and the chelator through a hydrogen, ionic, or covalent bond. Also, in accordance with this invention the divalent linker can comprise an indirect means for associating the chelator with the vitamin, or vitamin receptor binding derivative or analog, such as by connection through intermediary linkers, spacer arms, or bridging molecules. Both direct and indirect means for association must not prevent the binding of the vitamin, or vitamin receptor binding derivative or analog, to the vitamin receptor on the cell membrane for operation of the method of the present invention.

Covalent bonding of the vitamin, or vitamin receptor binding derivative or analog, and the chelator can occur, whether or not a linker is employed, through the formation of amide, ester or imino bonds between acid, aldehyde, hydroxy, amino, or hydrazo groups. For example, a carboxylic acid on the vitamin moiety or on the chelator can be activated using carbonyldiimidazole or standard carbodiimide coupling reagents such as 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and thereafter reacted with the other component of the conjugate, or with a linker, having at least one nucleophilic group, viz hydroxy, amino, hydrazo, or thiol, to form the vitamin-chelator conjugate coupled, with or without a linker, through ester, amide, or thioester bonds.

The radionuclides suitable for diagnostic imaging include radioisotopes of gallium, indium, copper, technetium and rhenium, including isotopes ¹¹¹In, ^{99m}Tc, ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga or ⁶⁸Ga. These radionuclides are cationic and are complexed with the chelator through the chelating group of the conjugate to form the vitamin-imaging agent conjugate.

The vitamin-imaging agent conjugates in accordance with the invention are utilized to selectively visualize, using scintigraphic imaging techniques, a population of cells in an animal wherein the population of cells uniquely expresses,